Practice
Featured experience
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
Mastercard $1.8 billion acquisition of BVNK
We are advising Mastercard on the transaction
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We are advising Sycamore Partners on the transaction
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Patrick Industries $258.75 million convertible notes offering
The 1.75% convertible notes are due 2028
Perion Network $180 million follow-on offering
We advised Perion on the offering of ordinary shares
Rockefeller Group JV with Park Tower for development in Greenpoint Landing, NY
We advised the Rockefeller Group on the joint venture
Target Global Acquisition I $200 million IPO
We advised Target Global Acquisition I, a SPAC, on its IPO and Nasdaq listing
Toronto-Dominion Bank $500 million notes offering
The investment-grade senior notes are due 2024
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes
Nubank $2.6 billion IPO
We advised Nubank on its dual listing on the NYSE and São Paulo Stock Exchange
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
GrowthCurve Capital acquisition of Mistplay
We advised GrowthCurve Capital on the transaction
Riverbed Technology emerges from chapter 11 bankruptcy
We advised an ad hoc group of first-lien term lenders in connection with Riverbed’s restructuring